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Abstract
Osteonecrosis and osteoporosis are frequent adverse effects of glucocorticoid therapy 
of systemic lupus erythematosus (SLE). Idiopathic osteonecrosis (ION) of the femoral 
head occurs in 3–40% of patients receiving glucocorticoid, and can also develop in other 
bones. Higher doses of glucocorticoid and steroid pulse therapy are considered to be risk 
factors for ION of the femoral head. To analyze these risk factors, it seems important to 
detect early changes in the femoral head by magnetic resonance imaging and to monitor 
early clinical events attributable to steroid therapy. Prophylaxis with statins and warfa-
rin remains debatable. The use of glucocorticoid is increase the risk of bone fractures. 
Bisphosphonate (BP) is used for its prevention and treatment of osteoporosis. Atypical 
femoral fracture (AFF) has been recently recognized as a complication associated with 
BP use. AFF is considered to be a form of stress fracture; localized periosteal thickening 
of the lateral cortex is often present at the fracture site. The thickening has been recently 
recognized as a complication associated with the use of antiresorptive agents such as 
BP and denosumab. As long-term BP/glucocorticoid use is a risk factor for beaking in 
patients with SLE , temporary withdrawal of BP administration should be considered.
Keywords: systemic lupus erythematosus, glucocorticoid, osteonecrosis, bisphosphonate, 
atypical femoral fracture
1. Introduction
Systemic lupus erythematosus (SLE) is a chronic, inflammatory, systemic autoimmune disease 
of unknown etiology characterized by production of antinuclear autoantibodies. It mainly 
affects young women and shows a broad spectrum of manifestations such as general fatigue, 
skin rash, fever, and arthritis and disorders involving the kidney, heart, and central nervous 
system. These organ involvements occur in patients with severer disease status and indicate 
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a poor prognosis. Glucocorticoid has been used as a first-line therapy for SLE. Glucocorticoid 
exerts strong anti-inflammatory effects and is widely used for the treatment of uncontrolled 
disease activity in patients with SLE, such as central nervous system lupus (CNS), severe 
lupus nephritis, and other life-threatening conditions [1]. Glucocorticoid therapy is success-
ful in most cases when high doses are employed, and as a result the prognosis of the SLE has 
improved remarkably. On the other hand, as glucocorticoid has adverse side effects on many 
organ systems, only the minimum effective dose is used for treatment. For example, skin thin-
ning and purpura are commonly observed, and the risk of both cataracts and glaucoma is 
increased. Glucocorticoid use is associated with an increased risk of ischemic heart disease and 
heart failure, and also an increased risk of gastritis, gastric ulcer, and gastrointestinal bleeding. 
In the musculoskeletal system, osteoporosis is one of the more serious adverse effects of gluco-
corticoid [2], and osteonecrosis is also a significant problem [3]. Bisphosphonate (BP) is a key 
drug used for prevention and treatment of osteoporosis. The risk of osteonecrosis caused by 
glucocorticoid is higher in patients with SLE. Glucocorticoid causes a dose-dependent, mild 
increase in the fasting glucose level and a greater increase in postprandial hyperglycemia in 
patients without preexisting diabetes mellitus (DM), whereas it worsens control of the blood 
glucose level in patients with DM. The adverse effect of glucocorticoid on atherosclerotic 
vascular disease is thought to be mediated in part by elevated levels of nonfunctional lipo-
protein. In patients with SLE, the adverse effects of glucocorticoid on lipid profiles are dose-
dependent, occurring only at prednisone doses exceeding 10 mg/day. Systemic glucocorticoid 
also has many effects on both innate and acquired immunity, resulting in a dose-dependent 
increase in the risk of infection, especially with common bacterial, viral, and fungal pathogens 
[4]. Conventional immunosuppressive agents such as mycophenolate mofetil, azathioprine, 
and cyclophosphamide are also widely used in the management of SLE, and current treat-
ment regimens optimize the use of these agents while minimizing their potential toxicity [5]. 
Tacrolimus may be particularly useful as adjunctive therapy in patients with persistent pro-
teinuria despite other therapies, and in the management of lupus nephritis in pregnancy. The 
advent of biological agents has advanced the treatment of SLE, particularly in patients with 
refractory disease. The CD20 monoclonal antibody rituximab and the anti-BLyS agent belim-
umab are widely used in clinical practice. The prognosis of SLE has improved markedly, and 
long-term survival has increased. Prior to 1955, fewer than 50% of patients survived 5 years 
after diagnosis whereas now, 10-year survival exceeds 90% [6 ]. Our recent data have also con-
firmed that the 5-year survival rates of patients diagnosed as having SLE before 1970, between 
1970 and 1979, between 1980 and 1989, between 1990 and 1999, and after 2000 were 71.4, 83.1, 
94.5, 93.4, and 96.4%, respectively. Previously, the causes of death in patients with SLE were 
mainly infection and renal disease, but recently atherosclerotic cardiovascular disease emerg-
ing in the long term has become a focus of concern. Musculoskeletal conditions that impair 
the quality of life have also become problematic, including osteonecrosis and atypical femoral 
fracture (AFF). Here we discuss osteonecrosis and AFF in patients with SLE.
2. Incidence, etiology, and pathogenesis
Idiopathic osteonecrosis (ION) of the femoral head occurs frequently (3–40%) in patients 
receiving glucocorticoid for underlying conditions such as nephrotic syndrome and renal 
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transplantation [7–10]. It is also known to occur as one of the serious complications of glu-
cocorticoid treatment of SLE. Among several factors related to ION, glucocorticoid therapy is 
considered to be one of essential importance [3]. There have been a lot of reports of ION onset 
in SLE patients to date, but the exact incidence of ION in this group is unknown. The etiol-
ogy or pathogenesis of this disorder has not been fully clarified, and no prophylaxis has been 
established to date. The risk of ION in SLE patients is considered to be due to both the SLE 
itself and the concomitant use of glucocorticoid because, in occasional cases, ION has been 
noted in the absence of glucocorticoid therapy [3]. In addition, the risk of developing ION has 
been linked to numerous factors such as glucocorticoid use, alcohol consumption, cigarette 
smoking, and several rheumatic diseases including SLE. Although the pathogenesis remains 
unclear, involvement of lipid metabolism abnormality [11], hypercoagulability [12], oxida-
tive stress [13], and vascular endothelial dysfunction [14] has been suggested from basic and 
clinical research. Several studies investigating the association of ION with steroid treatment 
have yielded conflicting results with regard to the cumulative dosage, maximum dose, route 
of administration, and duration of treatment. Glucocorticoid dose and duration seem to be 
important factors related to ION, but there is considerable controversy about this issue [3, 
15–20]. ION may develop in patients who have received high-dose, short-term, or long-term 
steroid. However, in the early phase, the relationship between steroid and ION has yet been 
not fully investigated. In our present study, the patients were treated with steroid for the first 
time, and our observation period was short. Additionally, the initial dose of prednisolone 
(PSL) for treatment of SLE has sometimes been determined according to the patient’s weight 
or body surface area (BSA) [21]. Therefore, we investigated the relationship of body mass 
index (BMI) [22] and BSA with the initial dose of PSL. We found that the initial dose of PSL, 
steroid pulse therapy, BMI, and BSA were not correlated with asymptomatic ION, similar to 
the results obtained by Sekiya et al. [23]. Also, we failed to identify any relationship between 
BMI, BSA, the initial dose of PSL per unit BW, the initial dose of PSL relative to BMI, or the 
initial dose of PSL relative to BSA. None of the factors evaluated were associated with asymp-
tomatic ION. Recent meta-analysis data have shown that the likelihood of ION developing 
in patients receiving glucocorticoid at more than 20 mg/day is significantly higher than in 
patients receiving less than 20 mg/day. In the early phase, corticosteroid at over 20 mg/day 
may trigger ION. In addition, it has been revealed that increasing the steroid dose at the time 
of SLE recurrence is a risk factor for development of new ION [24].
3. Timing of osteonecrosis-related ischemia in patients with SLE
Radiographically, at the earliest stage of ION, plain radiographs show normal features, 
whereas axial and coronal T1- and T2-weighted MR images show low-density signals in the 
femoral head (Figure 1).
From this viewpoint, osteonecrosis associated with renal transplantation can provide impor-
tant information. The band patterns on MRI correspond to repair tissue located between 
necrotic and intact areas [25, 26]. Thus, there is a time lag between the occurrence of ischemia 
and the appearance of the band pattern. It has been reported that 1 month after internal 
fixation of a femoral neck fracture, MRI can reveal band patterns in the femoral head away 
Idiopathic Osteonecrosis and Atypical Femoral Fracture in Systemic Lupus Erythematosus
http://dx.doi.org/10.5772/intechopen.68143
173
from the fracture line [27]. In patients who develop ION after renal transplantation, it is 
presumed that intraosseous ischemia occurs earlier than 6–12 weeks postoperatively [28, 29] 
when band patterns are observed on T1-weighted MRI. In experimental animal models of 
osteonecrosis, it has been shown that intraosseous ischemia occurs quite soon after admin-
istration of large doses of steroid, that is, on the fifth and third day, respectively. The total 
dose of steroid administered in the first 2 weeks after renal transplantation is related to ION 
development [30]. This suggests the occurrence of an event in the bone that may lead to the 
development of ION at a very early stage after steroid administration. The widespread use of 
MRI now makes it possible to detect osteonecrotic change in SLE patients soon after admin-
istration of glucocorticoid, thus facilitating early diagnosis. Nagasawa et al. reported that 
33% of patients developed ION within 3 months after the start of glucocorticoid treatment 
and that symptomatic ION became apparent at 2 years and beyond [31]. Radiographically, a 
subchondral radiolucency known as the crescent sign appeared at a late stage in ION, indi-
cating subchondral fracture. However, that study was a multicenter one, and several strate-
gies were selected for treatment of SLE according to the clinical conditions of the patients, 
resulting in slight differences among the participating hospitals. Several strategies have been 
selected for treatment of SLE in conformity with the clinical conditions of the affected patients, 
and there are many differences among hospitals, such as the indications for immunosuppres-
sants. However, for any study performed at a single institution, the strategy of treatment, the 
steroid selection, the initial dose of steroid, and concomitant drugs would be more uniform. 
In addition, the speed of steroid tapering would also be quite uniform. This would allow bet-
ter clarification of the background factors associated with ION. On the basis of this concept, 
we investigated the early development of ION in a cohort of strictly selected SLE patients 
using MRI and the early changes in laboratory parameters associated with steroid therapy 
[32].
4. Classification of osteonecrosis
Diagnosis of ION of the femoral head relies on the combination of clinical symptoms and 
radiographs and/or magnetic resonance imaging (MRI) changes. To evaluate the evolution 
of ION of the femoral head, the Ficat (Table 1) [33] and the Association Research Circulation 
Osseous (ARCO) classification (Table 2) [34] are generally used to evaluate both imaging 
modalities. For comparative purposes, these classifications need to be reliable and uniform 
definition to provide sufficient therapy options for the patient.
Figure 1. A T1-weighted image demonstrates a ring-like subchondral area of osteonecrosis (white arrow) present in the 
femoral head.
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5. Early changes in MRI features and laboratory parameters of SLE 
patients
In previous multicenter studies, several strategies were selected for treatment of SLE according 
to the clinical conditions of the patients, resulting in slight differences among the participating 
hospitals. This allowed us to investigate the very early development of ION at 3 months after 
Stage Radiographic signs Clinical features
0 Inconspicuous/normal findings 0 (“silent hip”)
I Inconspicuous findings or minor changes 
(slight patchy osteoporosis, blurring of 
trabecular pattern, subtle loss of clarity)
+
II A Diffuse/focal radiological changes 
(osteoporosis, sclerosis, cysts)
+
II B Subchondral fracture (“crescent sign”) 
segmental flattening of femoral head (“out-of-
round appearance”)
+
III Broken contour of femoral head, bone 
sequestrum, joint space normal
++
IV Flattened contour of femoral head, decreased 
joint space collapse of femoral head, acetabular 
osteoarthritic changes
+++
Table 1. Scheme of Ficat classification (1985).
Stage Radiological findings Subclassification
0 Positive: histology negative/normal: 
radiograph/CT/MRI/scintigraphy
−
I Positive: MRI and/or bone scintigraphy 
negative/normal: radiograph/CT
+
(a)
II Radiograph: sclerotic, cystic or 
osteoporotic changes of femoral head
+
(a)
III Radiograph: subchondral fracture 
(“crescent sign”)
+
(a)
IV Radiograph: flattening of femoral head ++ (b)
V Radiograph: flattening of femoral head 
and osteoarthritic changes: decreased 
joint space and acetabular changes
+++
(b)
VI Complete joint destruction −
Note: (a) Location of femoral head necrosis: (1) medial third, (2) median third, and (3) lateral third. Size of femoral head 
necrosis: (A) <15%, (B) 15–30%, (C) >30%.
(b) Intrusion degree of femoral head contour: (A) <2 mm, (B) 2–4 mm, and (C) >4 mm.
Table 2. Scheme of ARCO classification system (1992).
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the start of steroid therapy using MRI imaging to clarify the background factors associated 
with ION. We found that the prevalence of asymptomatic ION among our patients was 26.9%, 
similar to that described previously [23]. We found no differences in the clinical characteristics 
of the patients, such as sex, age, height, and body weight and clinical features. The Systemic 
Lupus Erythematosus Disease Activity Index (SLEDAI) is shown to be a valid and reliable measure 
of disease activity of SLE patients [35]. The SLEDAI score is assessed using a combination of clini-
cal history, physical examination, organ-specific function test and serological test. Almost all of our 
patients showed high or very high disease activity at the time of steroid initiation. However, 
the SLEDAI score was not correlated with asymptomatic ION [32]. In SLE, as is the case for 
antiphospholipid syndrome (APS), about 30–40% of patients have detectable antiphospholipid 
antibodies [36] and a positive lupus anticoagulant test and anticardiolipin antibody are detected 
in approximately 10–30% and 20–40% of patients, respectively. The prevalence of a so-called 
clinically significant anticardiolipin profile is considered to be about 30–40% [37]. APS antibod-
ies as a prothrombotic factor might predispose to ION by causing microvascular thrombosis. 
However, the link between APS antibodies and ION is controversial [38–41]. In our study, there 
was no significant association between APS antibody and ION [32]. A Japanese nationwide 
study revealed that cigarette smoking was an independent risk factor for ION [42]. However, in 
our present study, cigarette smoking was not correlated with ION in SLE patients [32].
6. Serological parameters and ION
Serological activity of SLE was determined on the basis of decreased CH50 and increased 
anti-DNA antibodies. We also investigated serological parameters such as C3, C4, CH50, and 
anti-ds DNA antibody, as well as renal function parameters such as the serum creatinine 
level, estimated glomerular filtration rate, and proteinuria. However, these factors were not 
correlated with ION. Thus, both initial serological disease activity and initial renal function, as 
the most common forms of organ involvement, did not appear to be correlated with ION [32]. 
Similar results were obtained in a previous single-center study [23].
7. Lipid levels, statins, and ION
Several studies of ION have indicated the association of lipid. Nagasawa et al. [31] investigated 
the rate of increase in serum total cholesterol (TC) levels 1 month after glucocorticoid admin-
istration in patients with new-onset SLE, and found that they were significantly high in the 
ION group. It was also found that lipid levels, and the rates of increase in almost all the TC and 
triglyceride (TG) parameters, were higher in the group that developed ION. TC levels tended 
to be higher than that in the non-ION group, and the maximum levels and increasing rates were 
significantly higher, suggesting that a rapid rise in serum lipids soon after an increase in glu-
cocorticoid dose might affect the onset of ION [23]. Our data suggested that the level of TG both 
before and after the initiation of steroid therapy was higher in patients with ION [32]. The TG level 
before PSL therapy was associated future risk of asymptomatic ION. As the association between TG 
before PSL therapy and the initial dose of PSL was not significant, the effect of TG before PSL 
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therapy on asymptomatic ION would not have been modified by the initial dose of subsequent 
PSL. Several studies have shown that a high TG level is a strong risk factor for stroke and ischemic 
heart disease [43–45]. ION is caused by partial or total interruption of blood flow to the femoral 
head, and SLE patients thought to develop asymptomatic ION through a similar mechanism. 
Additionally, it is well known that steroid therapy induces iatrogenic metabolic syndrome, and 
from this point of view, a high TG level is considered to be an important risk factor for asymp-
tomatic ION. Furthermore, the TC level after steroid therapy tended to be higher in patients with 
asymptomatic ION. However, the levels of high-density lipoprotein cholesterol (HDL-C) and 
low-density lipoprotein cholesterol (LDL-C) were not correlated with asymptomatic ION. As 
described previously, the TC level after 1 month of steroid treatment was significantly higher 
in patients with asymptomatic ION. Our data are similar to those reported previously [46]. 
In the early phase, lipids—especially TG—play an important role in the development of ION 
in patients with SLE. HMG-CoA reductase inhibitors (statins) have been widely used for the 
treatment of dyslipidemia as well as for prevention of ischemic heart disease. According to a 
chicken model, Wang et al. suggested that lovastatin prevented steroid-induced ION [47], and 
a study by Nishida et al. using a rabbit model also revealed that pitavastatin had a similar effect 
[48]. In humans, it has been reported that the incidence of osteonecrosis was decreased by 1% 
by administration of statins in a study of 284 patients with various disorders (excluding SLE) 
who received glucocorticoid treatment [49]. We used pravastatin, pitavastatin, lovastatin, and 
atorvastatin for prevention of ION, but no such preventive effect was observed [32]. Until now, 
no randomized controlled trial has been reported to successfully prevent steroid-induced ION. 
In patients with SLE, treatment with statins alone is insufficient for prevention of ION.
8. Prevention of osteonecrosis
In patients at risk of osteonecrosis, several factors are controllable, and thus prevention is the 
best approach. Hyperlipidemia and DM should be managed appropriately and alcohol con-
sumption minimized [42]. Smoking should also be avoided, if possible [50]. The dosage of 
glucocorticoid should be minimized as far as possible, as described previously. Statins may 
help to protect against osteonecrosis. One database review found that only 1% of 284 patients 
developed ION after treatment with statins before glucocorticoid use. In renal transplant 
recipients, among 338 patients who were treated with statins, 15 (4.4%) developed ION and 
among 2543 patients who were not treated with statins, 180 (7%) patients developed ION 
[49]. Antioxidant agents have been shown to inhibit osteonecrosis in animal models [51]. 
Further accumulation of similar studies is needed to clarify the preventive effect of statins 
against SLE-associated ION.
9. Treatment of ION
The management of ION is usually determined by the degree of femoral head involvement. 
If the subchondral shell remains intact, there is still a possibility of healing, but if collapse 
occurs, healing is impossible. If the necrotic area is small and there are no symptoms, ION 
Idiopathic Osteonecrosis and Atypical Femoral Fracture in Systemic Lupus Erythematosus
http://dx.doi.org/10.5772/intechopen.68143
177
should be followed up because some cases may spontaneously progress over time. If femo-
ral head ION is diagnosed early, core depression is a commonly used form of prophylac-
tic surgery to prevent the development of arthritis. One study has demonstrated long-term 
spontaneous repair of osteonecrotic lesions during low-dose glucocorticoid therapy [52]. 
Conservative treatment of ION involves limiting the degree of weight-bearing on the hip 
joint in conjunction with analgesia. In general, simple observation may be considered for 
asymptomatic lesions. Symptomatic lesions will likely progress to collapse, and if observa-
tion is chosen, the next joint-preserving procedure should be considered. Various forms of 
medication have been tried. BP is regularly used for prevention of insufficiency fractures, 
and several studies have shown that alendronate can reduce pain and slow the progression 
of collapse [53–55]. Treatment with BP is effective before subchondral collapse, but after sub-
chondral collapse, the effects of treatment for inhibiting destruction of the femoral head are 
limited. Lipid-lowering agents, especially statins, are hypothesized to have a protective effect 
against ON. The prevalence of a clinically significant antiphospholipid profile is approxi-
mately 20% in SLE patients, and these antiphospholipid antibodies are believed to contribute 
to ION though hypercoagulation. Accordingly, anticoagulation therapy has been tried for 
prevention of ION in SLE patients, and warfarin has been modestly beneficial in this respect. 
One study of 60 SLE patients receiving prednisolone at more than 40 mg/day found that 
treatment with warfarin significantly reduced the onset of ION [31]. Among various physical 
modalities, extracorporeal shockwave therapy, hyperbaric oxygen, and pulsed electromag-
netic therapy have yielded encouraging results, but further large prospective studies will be 
necessary to confirm these effects. Surgical treatments to prevent joint destruction include hip 
arthroplasty, core decompression, osteotomy, and vascularized bone grafting. Core decom-
pression is commonly performed as prophylactic surgery for pre-collapse osteonecrosis of the 
femoral head. This decreases intramedullary pressure within the femoral head and neck, and 
has been postulated to improve blood circulation to the femoral head. Core decompression is 
often combined with bone grafting to help regenerate healthy bone and support cartilage at 
the hip joint. Bone grafting involves transplantation of healthy bone tissue to an area of the 
body where it is needed. Another option that has had some degree of success is harvesting 
and in vitro culture of autologous mesenchymal stem cells and their re-implantation into the 
core decompression site [56–58]. Long-term studies to confirm the success of this approach 
are still underway. Hip arthroplasty is the most commonly performed procedure for postcol-
lapse lesions of the femoral head. Recent mid- and long-term studies have yielded satisfactory 
results [59]. Transtrochanteric anterior rotational osteotomy moves the symptomatic portion 
of the antero-superior femoral head out of the weight-bearing dome, enabling the normal 
posterior aspect of the head to bear weight, thus helping to preserve the joint [60]. These pro-
cedures have yielded favorable success rates, but are associated with a moderate risk of non-
union. Vascularized fibular grafting is a more complex procedure in which a segment of bone 
is taken from the fibula of the patient, along with the arterial and venous blood supply. This 
is then transplanted into a hole created in the femoral neck and head. Vascularized fibular 
grafting has yielded successful outcomes in patients with precollapse lesions and moderate 
success in those with postcollapse lesions [61]. Additionally, use of autogenic or allogeneic 
cortical bone grafts and cancellous bone grafts has yielded good results for the treatment of 
precollapse and/or early precollapse osteonecrotic lesions of the femoral head.
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10. Atypical femoral fracture
Glucocorticoid-induced osteoporosis (GIO) is an important problem in patients with SLE. BP 
is a key drug used for prevention and treatment of GIO. Patients with SLE often need to con-
tinue glucocorticoid and BP therapy for a long time, even if they are young. AFF has recently 
been recognized as a complication of long-term BP use [62, 63]. AFF is defined as a fracture 
located along the femoral diaphysis from just distal to the lesser trochanter to just proximal 
to the supracondylar flare, as distinguished from typical femoral fracture which occurs at the 
femoral neck or intertrochanteric area and is related to osteoporosis [63]. Diagnosis of AFF 
requires the presence of four of five major features (Table 3).
Beaking is one of these features, and is defined as localized periosteal or endosteal thickening 
of the lateral cortex at the fracture site. Since cortical thickening at the fracture site charac-
terizes stress fracture, the mechanism of AFF is considered to involve stress [63]. The age-
standardized incidence rates of AFF have been reported to be 16 per 100,000 person-years for 
patients treated with BPs over 5 years and 133 for those treated with BPs over 10 years [62], 
and AFF occurs much less frequently than osteoporosis-related fractures. However, once it 
occurs, it takes much time to heal [64, 65], and the daily life activities of the patient are often 
impaired. Risk factors for AFF other than long-term BP use include glucocorticoid therapy 
[66, 67], complicating connective tissue disease [67], lateral bowing of the femur [68, 69], a 
low level of serum 25-hydroxyvitamin D [66], and female gender [70]. Glucocorticoid ther-
apy has been reported to have an important impact on AFF [66, 67], although no significant 
To satisfy the case definition of AFF, the fracture must be located along the femoral diaphysis from just distal to the 
lesser trochanter to just proximal to the supracondylar flare.
In addition, at least four of the five major features must be present. None of the minor features is required but have 
sometimes been associated with these fractures.
Major features
The fracture is associated with minimal or no trauma, as in a fall from a standing height or less
The fracture line originates at the lateral cortex and is substantially transverse in its orientation, although it may 
become oblique as it progresses medially across the femur
Complete fractures extend through both cortices and may be associated with a medial spike; incomplete fractures 
involve only the lateral cortex
The fracture is noncomminuted or minimally comminuted
Localized periosteal or endosteal thickening of the lateral cortex is present at the fracture site (“beaking” or “flaring”)
Minor features
Generalized increase in cortical thickness of the femoral diaphyses
Unilateral or bilateral prodromal symptoms such as dull or aching pain in the groin or thigh
Bilateral incomplete or complete femoral diaphysis fractures
Delayed fracture healing
Table 3. ASBMR Task Force 2013 Revised Case Definition of AFFs [63].
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 association has yet been proved in several studies [71, 72]. Girgis et al. reviewed 152 femoral 
shaft fractures and classified 20 of them as AFF; they concluded that the use of glucocorticoid 
therapy for more than 6 months was significantly associated with AFF [66]. In a fracture loca-
tion-, age-, and gender-matched case-control study, Saita et al. reviewed 2238 hip and femoral 
shaft fractures and diagnosed 10 of them as AFF, concluding that glucocorticoid therapy and 
complicating connective tissue disease were significant risk factors for AFF [67]. We recently 
evaluated the incidence of latent femoral beaking (Figure 2), which may precede AFF, in 125 
patients with autoimmune diseases [65 (52%) with SLE] taking BP and glucocorticoid [73].
Our data revealed that the incidence of beaking was 8% and increased to 10% over 2 years. A 
case of complete AFF from the tip of the beaking occurred in one patient. The risk factors for 
beaking were BP therapy for a period of >4 years, age 40–60 years, and presence of diabetes 
mellitus [73]. Although few studies have investigated AFF in patients with SLE, the frequency 
of beaking in our study was thought to be higher than in conventional reports of AFF, possibly 
because all of the patients were taking BP (mean therapy duration 5.1 ± 2.7 years) and glucocor-
ticoid (mean dose 10.0 ± 3.8 mg). Both BP and prolonged glucocorticoid therapy reduce bone 
remodeling [64, 74], thus, impairing the healing of microdamage occurring during normal daily 
life activities. BP also changes bone plasticity [75], and glucocorticoid therapy leads to a dete-
rioration of bone quality [76]. Thus, a combination of BP and glucocorticoid therapies enhances 
microdamage accumulation, producing conditions in which beaking can easily occur. Generally, 
lateral bowing of the femur is considered to be a risk factor for AFF. Hyodo et al. indicated that 
Figure 2. X-ray of the hip joint showing beaking (white arrow).
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AFF located in the mid femur was significantly related to femoral bowing, whereas AFF in the 
proximal femur was related to glucocorticoid use [68]. In our previous study of patients with 
autoimmune diseases taking BP and glucocorticoid, the femoral beaking was mostly located at 
the subtrochanter, and was not related to lateral bowing of the femur [73]. Therefore, AFF and 
beaking in patients taking BP and glucocorticoid may generally occur irrespective of lateral fem-
oral bowing. In order to properly benefit from BP and to minimize the risk of AFF, a BP “drug 
holiday” has been proposed. Postmenopausal women treated orally with BP for over 5 years can 
be considered for such a break in drug therapy if they have no osteoporotic fractures, their hip 
T score is >−2.5 and their fracture risk is not high [62]. For patients with GIO, few studies have 
investigated the safety and effectiveness of temporary drug withdrawal, and further studies are 
required. Because of the high frequency of beaking in patients taking BP and glucocorticoid [73], 
regular femoral X-ray screening for beaking is strongly recommended for AFF prevention, and 
once beaking is detected, a BP drug holiday should be considered.
11. Conclusion
SLE is a chronic inflammatory autoimmune disease mainly affecting young women; the mor-
tality has recently been improved by treatments including glucocorticoid therapy. However, 
several adverse effects of glucocorticoid may decrease the quality of life. Even though some of 
these adverse effects have been overcome recently, AFF and ION are still persistent problems, 
and further work needs to be done to alleviate them.
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